A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VISUAL III
- Sponsors Abbott Healthcare; AbbVie
- 12 Jul 2017 This trial was completed in Spain according to European Clinical Trials Database record.
- 17 Jan 2017 Planned number of patients changed from 400 to 424.
- 17 Jan 2017 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History